AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®

OCALA, Fla., May 06, 2024 -- AIM ImmunoTech Inc.   today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® , AIM’s dsRNA product candidate being...

Related Keywords

United States ,American ,Thomask Equels , ,Immunotech Inc ,Exchange Commission ,Linkedin ,Facebook ,Executive Officer Thomas ,Private Securities Litigation Reform Act ,Markets ,